Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
16.31
-0.57 (-3.41%)
At close: Apr 28, 2026, 4:00 PM EDT
16.40
+0.09 (0.58%)
After-hours: Apr 28, 2026, 4:17 PM EDT
Amylyx Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | 87.37 | 380.79 | 22.23 | 0.29 | |
| Revenue Growth (YoY) | - | -77.05% | 1612.94% | 7700.00% | -56.15% | |
| Cost of Revenue | 90.4 | 228.72 | 153.63 | 96.44 | 44.04 | |
| Gross Profit | -90.4 | -141.35 | 227.16 | -74.21 | -43.76 | |
| Selling, General & Admin | 62.89 | 114.33 | 188.36 | 127.13 | 38.93 | |
| Operating Expenses | 62.89 | 114.33 | 188.36 | 127.13 | 38.93 | |
| Operating Income | -153.29 | -255.68 | 38.8 | -201.34 | -82.69 | |
| Interest & Investment Income | 9.3 | 13.81 | 16.16 | 4.29 | 0.04 | |
| Other Non Operating Income (Expenses) | -6.23 | -11.07 | -10.6 | -2.61 | 0.07 | |
| EBT Excluding Unusual Items | -150.22 | -252.94 | 44.36 | -199.66 | -82.58 | |
| Merger & Restructuring Charges | - | -22.85 | - | - | - | |
| Gain (Loss) on Sale of Investments | 5.53 | 9.86 | 9.94 | 2.06 | -0.12 | |
| Other Unusual Items | - | - | - | - | -5.23 | |
| Pretax Income | -144.69 | -302.14 | 54.3 | -197.6 | -87.93 | |
| Income Tax Expense | 0.05 | -0.39 | 5.03 | 0.77 | - | |
| Net Income | -144.74 | -301.74 | 49.27 | -198.38 | -87.93 | |
| Net Income to Common | -144.74 | -301.74 | 49.27 | -198.38 | -87.93 | |
| Shares Outstanding (Basic) | 95 | 68 | 67 | 58 | 7 | |
| Shares Outstanding (Diluted) | 95 | 68 | 70 | 58 | 7 | |
| Shares Change (YoY) | 38.78% | -2.64% | 19.65% | 788.13% | 8.37% | |
| EPS (Basic) | -1.53 | -4.43 | 0.73 | -3.39 | -13.35 | |
| EPS (Diluted) | -1.53 | -4.43 | 0.70 | -3.39 | -13.35 | |
| Free Cash Flow | -123.48 | -204.01 | 10.68 | -182.4 | -75.15 | |
| Free Cash Flow Per Share | -1.31 | -2.99 | 0.15 | -3.12 | -11.41 | |
| Gross Margin | - | -161.78% | 59.66% | - | - | |
| Operating Margin | - | -292.63% | 10.19% | -905.72% | -29013.33% | |
| Profit Margin | - | -345.36% | 12.94% | -892.38% | -30852.98% | |
| Free Cash Flow Margin | - | -233.50% | 2.80% | -820.50% | -26369.12% | |
| EBITDA | -152.77 | -254.77 | 39.89 | -200.85 | -82.64 | |
| EBITDA Margin | - | -291.60% | 10.48% | - | - | |
| D&A For EBITDA | 0.53 | 0.9 | 1.09 | 0.49 | 0.05 | |
| EBIT | -153.29 | -255.68 | 38.8 | -201.34 | -82.69 | |
| EBIT Margin | - | -292.63% | 10.19% | - | - | |
| Effective Tax Rate | - | - | 9.26% | - | - | |
| Revenue as Reported | - | - | - | 22.23 | 0.29 | |
| Advertising Expenses | - | - | 9.5 | 4.4 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.